Literature DB >> 22077388

Interactions between killer immunoglobulin-like receptors and their human leucocyte antigen Class I ligands influence the outcome of unrelated haematopoietic stem cell transplantation for thalassaemia: a novel predictive algorithm.

Roberto Littera1, Nicola Orrù, Giovanni Caocci, Marco Sanna, Marina Mulargia, Eugenia Piras, Adriana Vacca, Claudio Giardini, Maria G Orofino, Giuseppe Visani, Alice Bertaina, Giovanna Giorgiani, Franco Locatelli, Carlo Carcassi, Giorgio La Nasa.   

Abstract

In a study conducted on 114 patients undergoing unrelated donor haematopoietic stem cell transplantation (HSCT) for thalassaemia, we observed that the lack of activating killer immunoglobulin-like receptors (KIRs) on donor natural killer (NK) cells significantly increased the risk of graft-versus-host disease (GvHD) [hazard risk (HR) 4.2, 95% confidence interval (CI) 1.7-10.1, P = 0.002] and transplantation-related mortality (HR 4.7, 95% CI 1.6-14.2, P = 0.01). The risk of GvHD furthermore increased when recipients heterozygous for HLA-C KIR ligand groups (C1/C2) were transplanted from donors completely lacking activating KIRs (HR 6.1, 95% CI 1.9-19.2, P = 0.002). We also found that the risk of rejection was highest when the recipient was homozygous for the C2 HLA-KIR ligand group and the donor carried two or more activating KIRs (HR 6.8, 95% CI 1.9-24.4, P = 0.005). By interpolating the number of donor activating KIRs with recipient HLA-C KIR ligands, we created an algorithm capable of stratifying patients according to the immunogenetic risk of complications following unrelated HSCT. In clinical practice, this predictive tool could serve as an important supplement to clinical judgement and decision-making.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22077388     DOI: 10.1111/j.1365-2141.2011.08923.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  Use of Alefacept for Preconditioning in Multiply Transfused Pediatric Patients with Nonmalignant Diseases.

Authors:  Elizabeth O Stenger; Kuang-Yueh Chiang; Ann Haight; Muna Qayed; Leslie Kean; John Horan
Journal:  Biol Blood Marrow Transplant       Date:  2015-06-19       Impact factor: 5.742

Review 2.  What Unrelated Hematopoietic Stem Cell Transplantation in Thalassemia Taught us about Transplant Immunogenetics.

Authors:  Giorgio La Nasa; Adriana Vacca; Roberto Littera; Eugenia Piras; Sandro Orru; Marianna Greco; Carlo Carcassi; Giovanni Caocci
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-10-20       Impact factor: 2.576

3.  Entropy of human leukocyte antigen and killer-cell immunoglobulin-like receptor systems in immune-mediated disorders: A pilot study on multiple sclerosis.

Authors:  Maurizio Melis; Roberto Littera; Eleonora Cocco; Jessica Frau; Sara Lai; Elena Congeddu; Paola Ragatzu; Maria Serra; Valentina Loi; Roberta Maddi; Roberta Pitzalis; Sandro Orrù; Luchino Chessa; Andrea Perra; Carlo Carcassi
Journal:  PLoS One       Date:  2019-12-17       Impact factor: 3.240

4.  Innate Immune Determinants of Graft-Versus-Host Disease and Bidirectional Immune Tolerance in Allogeneic Transplantation.

Authors:  Anouk A J Hamers; Sunil K Joshi; Asha B Pillai
Journal:  OBM Transplant       Date:  2019-01-31

Review 5.  Conditioning Regimens in Patients with β-Thalassemia Who Underwent Hematopoietic Stem Cell Transplantation: A Scoping Review.

Authors:  Olga Mulas; Brunella Mola; Giovanni Caocci; Giorgio La Nasa
Journal:  J Clin Med       Date:  2022-02-09       Impact factor: 4.241

6.  Graft versus host disease in the bone marrow, liver and thymus humanized mouse model.

Authors:  Matthew B Greenblatt; Vladimir Vrbanac; Vladimir Vbranac; Trevor Tivey; Kelly Tsang; Andrew M Tager; Antonios O Aliprantis
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

Review 7.  Bone Marrow Homing and Engraftment Defects of Human Hematopoietic Stem and Progenitor Cells.

Authors:  Giovanni Caocci; Marianna Greco; Giorgio La Nasa
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-04-19       Impact factor: 2.576

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.